Bonesupport Holding Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Bonesupport Holding şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.004%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.004%
Gelecekteki Temettü Verimi	0.3%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

Oct 31

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

Mar 16

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Nov 06

Bonesupport Holding AB (publ)'s (STO:BONEX) Path To Profitability

Mar 31

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: BONEX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: BONEX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Bonesupport Holding Piyasaya Karşı Temettü Getirisi

BONEX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (BONEX)	n/a
Pazarın Alt %25'i (SE)	1.6%
Pazarın En İyi %25'i (SE)	4.6%
Sektör Ortalaması (Biotechs)	1.5%
Analist tahmini (BONEX) (3 yıla kadar)	0.3%

Önemli Temettü: BONEX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, BONEX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: BONEX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: BONEX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Bonesupport Holding Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Insider recently sold kr1.7m worth of stock

Now 21% undervalued

Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders

Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB.

Insider recently sold kr690k worth of stock

Bonesupport Holding AB (publ) to Report Q2, 2025 Results on Jul 15, 2025

Third quarter 2024 earnings released: EPS: kr0.47 (vs kr3.52 in 3Q 2023)

Now 22% undervalued

Price target increased by 8.6% to kr323

Consensus EPS estimates fall by 12%, revenue upgraded

Chief Executive Officer recently sold kr18m worth of stock

Second quarter 2024 earnings released: EPS: kr0.42 (vs kr0.08 in 2Q 2023)

Consensus EPS estimates fall by 14%

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Key Executive recently sold kr3.6m worth of stock

Insider recently sold kr478k worth of stock

First quarter 2024 earnings released

Full year 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to kr293

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 24%, revenue upgraded

Independent Director recently bought kr1.0m worth of stock

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Price target increased by 11% to kr179

Third quarter 2023 earnings released

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Independent Director recently bought kr1.1m worth of stock

Insider recently bought kr426k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold kr701k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold kr15m worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold kr1.4m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Price target increased by 17% to kr142

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Director recently bought kr203k worth of stock

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

No longer forecast to breakeven

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

Forecast to breakeven in 2023

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

Consensus forecasts updated

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Insider recently bought kr101k worth of stock

Forecast breakeven date moved forward to 2023

Price target increased to kr91.00

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Forecast breakeven date pushed back to 2024

Chairman of the Board recently bought kr1.2m worth of stock

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

We Think Bonesupport Holding (STO:BONEX) Can Easily Afford To Drive Business Growth

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Insider recently bought kr182k worth of stock

Third quarter 2021 earnings released

We're Not Worried About Bonesupport Holding's (STO:BONEX) Cash Burn

Bonesupport Announces Supplementary US Denovo Application Submitted

Chief Executive Officer recently bought kr343k worth of stock

Price target decreased to kr65.00

Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify

Chief Financial Officer recently bought kr87k worth of stock

Insider recently bought kr401k worth of stock